[Effectiveness of therapy of endometriosis with danazol and chlormadinone acetate and their effect on paraclinical parameters].
The effect of danazol in a dose of 400 mg-800 mg per day for 6 month was studied in 10 women and also chlormadinone acetate 2 X 2 mg per day. Clinical investigation and laboratory test were done before the therapy has been started, during treatment (after the 2 and the 6 month) and 2 month after the end of therapy. Two month after discontinuation of danazol 5 women were free of symptoms. The metabolic studies revealed significant changes in many biochemical parameters. Two month after discontinuation of chlormadinone acetate also 5 women were free of symptoms. The metabolic studies revealed significant changes only for the blood plateled concentration and serum bilirubin.
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D002715:Chlormadinone Acetate / Q000009:adverse effects / Q000627:therapeutic use*; D003613:Danazol / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006400:Hematocrit; D006801:Humans; D010976:Platelet Count / Q000187:drug effects; D011245:Pregnadienes / Q000627:therapeutic use*
D011245:Pregnadienes; D002715:Chlormadinone Acetate; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D003613:Danazol; D001663:Bilirubin
Die Effektivität der Therapie der Endometriose mit Danazol und Chlormadinonazetat sowie deren Einfluss auf paraklinische Parameter.